Mount Yale Investment Advisors LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 9,113 shares of the company’s stock, valued at approximately $273,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. NewEdge Wealth LLC boosted its holdings in shares of Genmab A/S by 50.7% during the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock worth $3,820,000 after acquiring an additional 40,382 shares during the period. SG Americas Securities LLC boosted its stake in shares of Genmab A/S by 360.5% in the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after buying an additional 23,094 shares during the period. Harding Loevner LP raised its position in Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares in the last quarter. Capital International Investors raised its position in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after purchasing an additional 315,355 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after purchasing an additional 3,770 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.
Genmab A/S Trading Up 0.4 %
Shares of NASDAQ:GMAB traded up $0.10 during mid-day trading on Monday, reaching $28.48. The company had a trading volume of 706,324 shares, compared to its average volume of 585,503. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 1.01 and a beta of 0.97. The company’s 50-day moving average price is $27.03 and its 200-day moving average price is $28.38. Genmab A/S has a one year low of $24.53 and a one year high of $41.58.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Truist Financial upped their price target on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, July 18th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, BTIG Research lifted their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $49.50.
View Our Latest Stock Analysis on GMAB
Genmab A/S Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- What Investors Need to Know About Upcoming IPOs
- Survey: Top 175 Fittest Retirement Locations in America
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- How is Compound Interest Calculated?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.